Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 3/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2859135 | 0.89 | ADRA1B (0.32) | MEN1KMT2AADRA1BHPGD | |
| SCHEMBL2867800 | 0.85 | FBP1 (0.36) | PDCD1CD274MEN1KMT2AADRA1B | |
| SCHEMBL2865955 | 0.82 | ALDH1A1 (0.33) | MEN1KMT2AADRA1BKDM4ECYP2D6 | |
| SCHEMBL2867795 | 0.78 | ADRA1B (0.34) | PDCD1CD274ADRA1BKDM4EALDH1A1 | |
| SCHEMBL772106 | 0.77 | HPGD (0.38) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL13476653 | 0.77 | CHEK1 (0.30) | — | |
| SCHEMBL2156447 | 0.70 | RAF1 (0.40) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL2156283 | 0.70 | PTPN1 (0.37) | MEN1KMT2AADRA1BKDM4EALDH1A1 | |
| SCHEMBL12510203 | 0.70 | KDM4C (0.30) | — | |
| SCHEMBL2987902 | 0.68 | LMNA (0.45) | MEN1KMT2AKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7659263-B2 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-02-09 | — | — | US | disclosed |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | TPMT, JAK2, GTF3C5 | PDCD1 566/4885CD274 746/4885MEN1 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.